Grandeur Peak Global Advisors’s Charles River Laboratories CRL Stock Holding History

Grandeur Peak Global Advisors’s Portfolio CRL Stock Details CRL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-30,055	Closed	-$5.55M	–	116
2024 Q4	$5.55M	Sell	30,055 -20,488	-41%	-$3.95M	0.49%	53
2024 Q3	$9.96M	Sell	50,543 -23,747	-32%	-$4.94M	0.83%	35
2024 Q2	$15.3M	Buy	74,290 +11,207	+18%	+$2.54M	1.23%	20
2024 Q1	$17.1M	Sell	63,083 -10,569	-14%	-$2.52M	1.36%	18
2023 Q4	$17.4M	Buy	73,652 +18,669	+34%	+$3.67M	1.23%	18
2023 Q3	$10.8M	Buy	+54,983	New	+$11.3M	0.81%	25

Other funds holding CRL

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Kayne Anderson Rudnick Investment Management Los Angeles, California $32.2B AUM 10.98% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Allspring Global Investments Charlotte, North Carolina $65.2B AUM 39.42% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Impactive Capital New York City, New York $1.4B AUM 13.97% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Grandeur Peak Global Advisors's CRL Position: Q1 2025 in Review

Grandeur Peak Global Advisors sold out of Charles River Laboratories (CRL) in Q1 2025, closing a stake of 30,055 shares — an estimated $5.55M sold.

Grandeur Peak Global Advisors first reported a position in CRL in Q3 2023 and held it in 6 quarters. The position peaked at $17.4M in Q4 2023. 561 funds tracked by Wall St. Rank hold CRL as of Q1 2025.

Grandeur Peak Global Advisors reported no remaining Charles River Laboratories position as of Q1 2025 after selling out during the quarter.
Grandeur Peak Global Advisors sold 30,055 Charles River Laboratories shares in Q1 2025, an estimated $5.55M.
Grandeur Peak Global Advisors first reported a position in Charles River Laboratories in Q3 2023 and held it in 6 quarters.
Grandeur Peak Global Advisors's Charles River Laboratories position peaked at $17.4M in Q4 2023.
561 funds tracked by Wall St. Rank held Charles River Laboratories as of Q1 2025.

Based on Grandeur Peak Global Advisors's 13F filing for Q1 2025, filed 15 May 2025.